Dapagliflozin for the treatment of type 2 diabetes

Annals of Pharmacotherapy

Volumn 43, Issue 7-8, 2009, Pages 1286-1293

  Brooks, Amie McCord ^a   Thacker, Stacey M ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

Dapagliflozin; SGLT2 inhibitor; Sodium glucose cotransporter inhibition

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; URINE VOLUME; UROGENITAL TRACT INFECTION; VULVOVAGINITIS;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 67651099002     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M212     Document Type: Article

References (35)

1. National diabetes fact sheet, 2007. Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf (accessed Apr 2 2009).
2. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-268
3. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(suppl 1):S13-61.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 35). Lancet 1998;352:864-865
6. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993;329:978-986
7. Reichard P, Nilsson B, Roseqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-309 (Pubitemid 23210681)
8. Beaton S, Nag S, Gunter M, et al. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 2004;27:694-698 (Pubitemid 38280535)
9. Saaddine J, Engelgau M, Beckles G, et al. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565-574 (Pubitemid 34407040)
10. Harris M. Health care and health status outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-758 (Pubitemid 30414188)
11. Nathan D, Buse J, Davidson M, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008;31:1-11.
12. Kooy A, Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-625
13. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. A scientific review. JAMA 2002;287:360-372
14. Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
15. Endmann E, Dormandy J, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive Study. J Am Coll Cardiol 2007;49:1772-1780 (Pubitemid 46629127)
16. Lincoff A, Wolski K, Nicholls S, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188 (Pubitemid 47403104)
17. DeFronzo R, Ratner R, Han J, et al. Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100 (Pubitemid 40616618)
18. AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration to Develop and Commercialise Dapagliflozin in Japan. AstraZeneca. www.astrazeneca.com/media/latest-press-release/2008/427294611?itemId=4369714 (accessed 2009 Feb 2).
19. Wright EM. Renal Na+ -glucose co-transporters. Am J Physiol Renal Physiol 2001;280:10-18
20. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-1729
21. Pajor AM, Randolph KM, Kerner SA, Smith CD. Inhibitor binding in the human renal low- and high-affinity Na+/glucose co-transporters. J Pharmacol Exp Ther 2008;324:985-991
22. Wells RG, Pajor AM, Kanai Y, et al. Cloning of a human kidney cDNA with similarity to the sodium-glucose co-transporter. Am J Physiol 1992;263:F459-65.
23. Kasahara M, Maeda M, Hayashi S, et al. A missense mutation in the Na+/glucose co-transporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein. Biochim Biophys Acta 2001;1536:141-147 (Pubitemid 32530813)
24. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular re-absorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008;62:1279-1284
25. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose re-absorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocrine Pract 2008;14:782-790
26. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-38
27. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-1149
28. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose co-transporter (SGLT2). Hum Genet 2002;111:544-547 (Pubitemid 36075086)
29. Sorof J, Tang W, List J. Pharmacodynamic effects of dapagliflozin (BMS-512148), a potent selective inhibitor of sodium-glucose co-transporter 2 (SGLT2) in healthy individuals and patients with type 2 diabetes mellitus (T2DM) (abstract). J Am Soc Nephrol 2008;19:TH-PO1021.
30. List JF, Woo V, Morales E, et al. Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657
31. Feng Y, Zhang L, Komoroski B, et al. Population pharmacokinetic analysis of dapagliflozin in healthy and subjects with type 2 diabetes mellitus (abstract). Clin Pharmacol Ther 2008;83(suppl 1):S72-S1000:PIII-71.
32. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-519 DOI 10.1038/clpt2008.250
33. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-526 DOI 10.1038/clpt.2008.251
34. National Institutes of Health. ClinicalTrials.gov. Search for clinical trials. www.clinicaltrials.gov/ct2/results?term=dapagliflozin (accessed 2009 Apr 9).
35. Leslie B, Tang W, List JF. Renal effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin (BMS-512148) in patients with type 2 diabetes mellitus (T2DM). J Am Soc Nephrol 2008;19:THPO1022.